Status:
TERMINATED
Alternation of Non-alcoholic Fatty Liver Disease (NAFLD) and Cardiovascular Risks After Liftestyle Modification: A Ultrasound Attenuation Imaging-Based Study
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Non-alcoholic Fatty Liver Disease
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The prevalence of obesity has significantly increased over the last few decades. The excessive fat accumulation in undesired areas in obese patients may lead to various complications, such as cardiova...
Eligibility Criteria
Inclusion
- With age range of 18-65 years.
- With diagnosis of NAFLD.
- BMI =27.5- 32.4kg/m2 for moderate obesity (Asian population)
- Written consent form obtained.
Exclusion
- Other kind of hepatic diseases or under medications known to affect liver fat accumulation.
- Excessive alcohol consumption (\>20g/d for men and \>10g/d for women).
- Subjects using thyroid hormones, oestrogens, amiodarone, steroids, tamoxifen and beta blockers (e.g. propranolol).
- Body weight \>250kgs and or/ waist circumference \> 150cm.
Key Trial Info
Start Date :
July 2 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2023
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04440540
Start Date
July 2 2020
End Date
June 30 2023
Last Update
February 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Chinese University of Hong Kong, Prince of Wale Hospital
Hong Kong, Shatin, Hong Kong